DK1159968T3 - Attenuated strains of Dengue virus and their use in a vaccine composition - Google Patents

Attenuated strains of Dengue virus and their use in a vaccine composition

Info

Publication number
DK1159968T3
DK1159968T3 DK00420113T DK00420113T DK1159968T3 DK 1159968 T3 DK1159968 T3 DK 1159968T3 DK 00420113 T DK00420113 T DK 00420113T DK 00420113 T DK00420113 T DK 00420113T DK 1159968 T3 DK1159968 T3 DK 1159968T3
Authority
DK
Denmark
Prior art keywords
dengue virus
attenuated strains
vaccine composition
serotype
attenuated
Prior art date
Application number
DK00420113T
Other languages
Danish (da)
Inventor
Nath Bhamarapravat
Sutee Yoksan
Original Assignee
Univ Mahidol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mahidol filed Critical Univ Mahidol
Application granted granted Critical
Publication of DK1159968T3 publication Critical patent/DK1159968T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Isolated, attenuated strains (A) of Dengue virus (DV) designated 16007 PDK13 (serotype 1); 16881 PDK53 (serotype 2); 16562 PGMK 30-Frhl3 (serotype 3) and 1036 PDK48 (serotype 4), deposited as CNCM I-2480, -2481, -2482 and -2483, respectively, are new. An Independent claim is also included for a vaccine containing at least one of (A), or its derivative.
DK00420113T 2000-05-30 2000-05-30 Attenuated strains of Dengue virus and their use in a vaccine composition DK1159968T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00420113A EP1159968B1 (en) 2000-05-30 2000-05-30 Attenuated strains of Dengue virus and their use in a vaccine composition

Publications (1)

Publication Number Publication Date
DK1159968T3 true DK1159968T3 (en) 2009-02-23

Family

ID=8174060

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00420113T DK1159968T3 (en) 2000-05-30 2000-05-30 Attenuated strains of Dengue virus and their use in a vaccine composition

Country Status (7)

Country Link
EP (1) EP1159968B1 (en)
AT (1) ATE412738T1 (en)
CY (1) CY1108666T1 (en)
DE (1) DE60040652D1 (en)
DK (1) DK1159968T3 (en)
ES (1) ES2315221T3 (en)
PT (1) PT1159968E (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10655110B2 (en) 2015-11-27 2020-05-19 Km Biologics Co., Ltd. Multivalent dengue vaccine composition comprising a mixture of attenuated dengue viruses from different serotypes

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006257621B2 (en) 2005-06-17 2011-08-11 Centers For Disease Control And Prevention Dengue serotype 2 attenuated strain
CA2611934C (en) * 2005-06-17 2015-11-03 Sanofi Pasteur Dengue serotype 1 attenuated strain
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
AR061197A1 (en) * 2006-06-07 2008-08-13 Sanofi Pasteur DENGUE VIRUS 3 CEPAS VIVAS ATENUADAS
FR2903605A1 (en) 2006-07-12 2008-01-18 Sanofi Pasteur Sa IMMUNIZATION METHOD AGAINST THE FOUR SEROTYPES OF DENGUE
FR2906724B1 (en) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa METHOD OF IMMUNIZATION AGAINST THE 4 SEROTYPES OF DENGUE.
FR2909286B1 (en) * 2006-12-01 2012-06-08 Sanofi Pasteur IMMUNIZATION METHOD AGAINST THE 4 SEROTYPES OF DENGUE
MX2010008799A (en) 2008-03-05 2010-09-07 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition.
EP2143440A1 (en) 2008-07-09 2010-01-13 Sanofi Pasteur Stabilising agent and vaccine composition comprising one or several attenuated living flavivirus
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
CN104812408A (en) 2012-07-24 2015-07-29 赛诺菲巴斯德有限公司 vaccine composition for preventing dengue virus infection
SG11201500412TA (en) 2012-07-24 2015-02-27 Sanofi Pasteur Vaccine compositions
BR112015012515B1 (en) 2012-11-30 2023-04-11 Sanofi Pasteur USE OF ANTIGENS, NUCLEIC ACID CONSTRUCTS OR VIRAL VECTORS CAPABLE OF EXPRESSING A VIRUS-LIKE PARTICLE (VLP) OF DENGUE AND A VACCINE AGAINST MEASLES, A VACCINE AGAINST MUMPS AND A VACCINE AGAINST RUBELLA
MX374519B (en) 2013-03-15 2025-03-06 Us Gov Health & Human Services COMPOSITIONS AND METHODS OF CHIMERICAL CONSTRUCTIONS OF THE DENGUE VIRUS IN VACCINES.
BE1024160B9 (en) 2015-12-22 2017-12-06 Glaxosmithkline Biologicals Sa IMMUNOGENIC FORMULATION
EP3691681A1 (en) 2017-10-05 2020-08-12 Sanofi Pasteur Compositions for booster vaccination against dengu
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040933A1 (en) * 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10655110B2 (en) 2015-11-27 2020-05-19 Km Biologics Co., Ltd. Multivalent dengue vaccine composition comprising a mixture of attenuated dengue viruses from different serotypes

Also Published As

Publication number Publication date
EP1159968A1 (en) 2001-12-05
EP1159968B1 (en) 2008-10-29
PT1159968E (en) 2008-11-20
DE60040652D1 (en) 2008-12-11
ES2315221T3 (en) 2009-04-01
CY1108666T1 (en) 2014-04-09
ATE412738T1 (en) 2008-11-15

Similar Documents

Publication Publication Date Title
CY1108666T1 (en) DANGEROUS EXPLOSIVE EXECUTIVE STABILITY AND USE IN A VACCINE COMPOSITION
EA200300023A1 (en) 3'-PROCEDURES 2'-DEOXY-β-L-NUCLEOSIDES
BRPI0309631A8 (en) tetravalent dengue vaccine containing a trivial deletion of 30 nucleotides in the utr-31 'of dengue types 1,2,3 and 4, or chimeric dengue antigenic viruses 1,2,3 and 4
RS100504A (en) Hepatitis c virus inhibitors
EA200000840A1 (en) ANTI-VIRUS DERIVATIVES OF PYRIMIDINE
ECSP045300A (en) VIRAL ANTIGENS
BRPI9911870B8 (en) swine parvovirus and circovirus vaccine
IS8448A (en) Hepatitis C virus inhibition
NO20026044L (en) Treatment of human papillomavirus
DK1200418T3 (en) Nematodicidal trifluorobutene
NO20025627L (en) Methods and compositions for treating hepatitis C virus
EP1399163A4 (en) COMPOUNDS, METHODS AND COMPOSITIONS FOR THE TREATMENT OF BOVINE VIRAL DIARRHEA (VBVD) INFECTION AND HEPATITIS C (HCV) VIRUS INFECTION
NO985066L (en) Therapeutic treatment for VEGF-related diseases
ATE265535T1 (en) PHARMACEUTICAL COMPOSITION AGAINST TUMORS AND INFECTIONS CAUSED BY PAPILLOMA VIRUSES
DK1075284T3 (en) Use of a vital dye to facilitate surgical intervention in vitreoretinal kurugi
WO2002072803A3 (en) Subgenomic replicons of the flavivirus dengue
DE60006825D1 (en) SEROTONERGE BENZOFURANE
ES2154879T3 (en) ANTIVIRICAL COMPOUNDS.
DE69703672D1 (en) Antivirus compounds
ES2155239T3 (en) ANTIVIRICAL COMPOUNDS.
ATE109139T1 (en) MEANS OF PROTECTING PLANTS AGAINST DISEASES.
NO20015202L (en) <beta> -Hydroxyalkylamides, process for their preparation and use
ATE469902T1 (en) AMORPHOUS SUBSTANCE OF A TRICYCLIC TRIAZOLOBENZAZEPINE DERIVATIVE
ATE203008T1 (en) ANTIVIRUS COMPOUNDS
DK1149901T3 (en) Mutants of pestiviruses and vaccines containing them